Related Experiment Video
Updated: Aug 7, 2026
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Stem cell cardiomyoplasty: state-of-the-art
1Research and Development Unit, National Heart Centre, 17 Third Hospital Avenue, Singapore 168752.
Insights
Cellular therapy offers a promising new treatment for advanced congestive heart failure (CHF) when other options fail. Ongoing research aims to optimize cell types, delivery methods, and timing for maximum therapeutic benefit in heart failure patients.
Area of Science:
- Cardiology and Regenerative Medicine
Background:
- Congestive heart failure (CHF) is a leading cause of hospitalization.
- Current treatments for end-stage CHF, like heart transplantation, are limited.
- Cellular therapy presents a novel therapeutic avenue for advanced heart failure.
Purpose of the Study:
- To review the current state of cellular therapy for congestive heart failure.
- To summarize recent preclinical and clinical findings.
- To identify key areas for future research and optimization.
Main Methods:
- Review of existing scientific literature on cellular therapy for CHF.
- Analysis of data from preclinical and clinical studies.
- Synthesis of information on cell types, delivery, and timing.
Main Results:
- Various cell types show encouraging results in preclinical and clinical settings.
- Cellular therapy is a potential alternative for end-stage heart failure.
- Several critical factors require further optimization for efficacy.
Conclusions:
- Cellular therapy is a rapidly evolving and promising field for CHF treatment.
- Further research is needed to optimize cell type, number, delivery route, and timing.
- This approach holds potential for patients with advanced heart failure unresponsive to current therapies.
Abstract:
Congestive heart failure (CHF) remains the most common diagnosis made in cardiology wards today. No long-term therapeutic option for end-stage CHF is available except for orthotopic heart transplant. Cellular-based therapy has emerged as a potential new therapy for patients with advanced heart failure. Different cell types are being explored in preclinical and clinical studies with encouraging results. Critical issues, such as types of cells, ideal number of cells, route of delivery, timing and targets of delivery, remain to be optimised to maximise the benefits of the cell therapy. In this review, we seek to summarise the latest data and postulate future directions in this potentially exciting field.
